Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects

European Journal of Clinical Pharmacology

Volumn 58, Issue 12, 2003, Pages 795-802

  Hermann, Robert ^a   Knebel, Norbert G ^a   Niebch, Georg ^a   Richards, Lyette ^b   Borlak, Juergen ^c   Locher, Mathias ^a  

^a Viatris Inc   (Germany)

^b WYETH AYERST RESEARCH   (United States)

^c FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Lamotrigine Pharmacokinetics; Retigabine

Indexed keywords

ANTICONVULSIVE AGENT; DRUG METABOLITE; LAMOTRIGINE; RETIGABINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COMPETITION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0038293217     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0558-6     Document Type: Article

References (30)

1. Rundfeldt C, Netzer R (2000) The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary cells transfected with human KCNQ2/3 subunits. Neurosci Lett 281:73-76
2. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen US, Dixon JE, Mc Kinnon D (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282:1890-1893
3. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA et al (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58:253-262
4. Wickenden AD, Yu WF, Zou A, Jegla T, Wagoner PK et al (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58:591-600
5. Wickenden AD, Zou AR, Wagoner PK, Jegla T (2001) Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 132:381-384
6. Hirsch E, De Saint-Martin A, Marescaux C (1999) Benign neonatal familial convulsions: a model of idiopathic epilepsy. Rev Neurol (Paris) 155:463-467
7. Rundfeldt C, Netzer R (2000) Investigation into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neuro-transmission and with voltage gated Na+ and Ca+ + channels. Arzneimittelforschung 50:1063-1070
8. Kapetanovic IM, Rundfeldt C (1996) A new anticonvulsant compound. CNS Drug Rev 2:308-321
9. Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J et al (2002) Retigabine. In: Bialer M et al (eds) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51:36-38
10. McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM (1997) In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 27:431-441
11. Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B et al (1999) Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 27:605-612
12. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel NG, Getsy J et al (2002) Multiple-dose linear dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharm 42:175-182
13. Magdalou J, Herber R, Bidault R, Siest G (1992) In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 260:11661173
14. Green MD, Tephly TR (1998) Glucuronidation of amine substrates by purified and expressed UDP-glucuronyltransferase proteins. Drug Metab Dispos 26:860-867
15. Peck AW (1991) Clinical pharmacology of lamotrigine. Epilepsia 32:S9-S12
16. Elwes RD, Binnie CD (1996) Clinical pharmacokinetics of newer antiepileptic drugs: lamotrigine, vigabatrin, gabapentin, and oxcarbazepine. Clin Pharmacokinet 30:403-415
17. Rambeck B, Wolf P (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25:433-443
18. Richens A (1992) Pharmacokinetics of lamotrigine. In: Richens A (ed) Clinical update on lamotrigine: a novel entiepileptic agent. Wells Medical Ltd, Tunbridge Wells, pp 21-27
19. Yau MK, Adams MA, Wargin WA, Lai AA (1992) A single-dose and steady-state pharmacokinetic study of lamictal in healthy male volunteers. Third International Cleveland Clinic, Bethel Epilepsy Symposium, Cleveland, OH, USA
20. Knebel NG, Grieb S, Leisenheimer S, Locher M (2000) Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 748:97-111
21. Sallustio BC, Morris RG (1997) High performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. Ther Drug Monit 19:688-693
22. Lensmeyer GL, Gidal BE, Weibe DA (1997) Optimized high performance liquid chromatography method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine and carbamazepine-epoxide. Ther Drug Monit 19:292-300
23. Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications, 2nd edn. Lea & Febiger, Philadelphia
24. Schuirmann D (1987) A comparison of the two one-sided test procedures and the power approach for assessing the equivalence of average bioavailability. J Pharm Biopharm 15:657-680
25. Committee for proprietary medicinal products (1995) Note for guidance on the investigation of drug interactions. CPMP/EWP/560/95
26. Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457-465
27. Ferron GM, Paul J, Richards L, Getsy J, Troy S (2001) Retigabine does not alter the pharmacokinetics of a low dose oral contraceptive in women. Neurology 56[Suppl 3]:P05.052
28. Ferron GM, Patat A, Parks V, Troy S (2001) Lack of pharmacokinetic interaction between retigabine and phenobarbital at steady-state in healthy subjects. Clin Pharmacol Ther 69:48
29. Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, Richards L, Cnota HP, Troy S (2003) Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 73:61-70
30. Potschka H, Fedrowitz M, Loscher W (2002) P-glycoprotein mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327:173-176